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Growing interest in the use of lentiviral (LV) vectors for gene therapy 
applications has resulted in demand for production processes that are 
amenable to large scale. However, up-scaling LV manufacturing poses 
a number of challenges for process developers and regulatory bodies, 
which need to be overcome in order to cost effectively generate a gene 
therapy product in large quantities. Recently there has been progress in 
developing workflows capable of producing and processing LV vector at 
sufficient levels for human gene therapy applications. Accordingly, this 
article will cover the current state of LV upstream and downstream pro-
cessing, ongoing challenges of up-scaling manufacturing, recent advances 
and improvements, and future perspectives.
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STRATEGIES FOR SCALE-UP &  
SCALE-OUT
A range of genetic and acquired 
diseases are potential candidates for 
lentivirus (LV) mediated gene ther-
apy, with multiple clinical trials al-
ready showing promising results in 
regard to safety and efficacy [1–4]. 
LV vectors offer many beneficial 
properties for use as a gene trans-
fer tool including persistent gene 
expression due to stable integration 
into the genome of the target cells, 
transduction of both dividing and 
non-dividing cells, a large packag-
ing capacity [5], and the ability to 
be pseudotyped with other viral 
envelope proteins thereby altering 
tissue tropism [6]. LVs are consid-
ered safer than other viral vectors 
as they typically have lower immu-
nogenicity [5], and exhibit reduced 
oncogenesis risk compared to earlier 
γ-retroviral vectors [7]. These favor-
able characteristics have attracted 
researchers to LV vectors for use in 
gene therapy.
Human immunodeficiency virus 
1 (HIV-1) based vectors have been 
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extensively studied for gene thera-
py applications, although other LVs 
including HIV-2, simian immuno-
deficiency virus (SIV), feline immu-
nodeficiency virus (FIV), caprine 
arthritis-encephalitis virus (CAEV) 
and equine infectious anemia virus 
(EIAV) are also being explored [8]. 
With interest in the use of LV vectors 
rapidly growing, there is an increas-
ing need for large volumes of con-
centrated LVs for use in pre-clinical 
and clinical settings, and according-
ly, the means to produce such quan-
tities [9]. Although LVs are routinely 
produced at a small to medium scale 
in laboratories for basic research and 
in vivo use in small animal models, 
up-scaling these methods has proven 
challenging. Difficulties arise sur-
rounding the development of stable 
packaging cell lines (PCLs) for LV 
production, the restrictive nature 
of adherent cell lines used in tran-
sient transfection, and the need for 
efficient purification processes that 
preserve vector function. The high 
cost of goods (COGs) associated 
with LV manufacturing is also one of 
the greatest impediments to success-
ful translation of gene therapies. As 
such, accelerating the development 
of large-scale LV manufacturing pro-
cesses that are capable of producing 
high  quality  vector  in  a  cost-effec-
tive manner will be essential.
This article will present an update 
on the current state of LV produc-
tion, available upstream and down-
stream processes, their advantages 
and limitations, as well as the  chal-
lenges to come.
UPSTREAM PROCESSING 
The most significant challenge for 
upstream processing (USP) of LVs 
is overcoming low titers. Typically, 
LVs are made using two routes of 
production: the use of stable PCLs; 
or the transient transfection of ad-
herent human embryonic kidney 
(HEK) 293T cells (or their genet-
ic derivatives) using multiple plas-
mids [9]. Both approaches are cur-
rently being examined for use in a 
large-scale manufacturing setting, 
and they each have advantages and 
disadvantages when generating a 
clinical-grade product [5]. Anoth-
er technological hurdle associated 
with large-scale LV production is 
the limited scalability of adherent 
cell lines used in both stable and 
transient expression systems. Ac-
cordingly, there has been recent 
development of tools that allow for 
modest scale-up of adherent cells 
[10], as well as attempts to move to 
suspension-based production [11].
LV production using stable 
packaging cell lines 
A PCL approach is ideal because it 
allows for continuous and reproduc-
ible production of large batches of 
vector [12]. PCLs also have the ca-
pacity to be adapted to serum-free, 
suspension culture systems, which 
allows for ease of up-scale in bio-
reactors, and is preferable for clini-
cal-grade production. Despite these 
advantages, there have been greater 
challenges in establishing PCLs for 
LVs when compared to other retro-
viral vectors [8]. Cytotoxic effects of 
HIV-1 proteins such as rev and gag-
pol, as well as the commonly used 
vesicular stomatitis virus glycopro-
tein (VSV-G) envelope, all prevent 
constitutive expression [5]. At-
tempts have been made to overcome 
this issue by developing inducible 
expression systems for cytotoxic 
proteins (e.g., Tet-on system) [13]. 
Although successfully generated, in-
ducible cell lines are not routinely 
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used as additional downstream pro-
cessing (DSP) steps are needed to 
remove inducing agents, and vector 
yields remain relatively low due to 
declines in titer post-induction [9]. 
Tet-off systems have also been 
developed where removal of dox-
ycycline (a tetracycline analogue) 
induces expression; however, this 
approach requires a complete media 
change that is unfeasible at large-
scales, and there have been reports 
of considerable delays in attaining 
peak expression following doxycy-
cline removal [14]. Despite difficul-
ties in producing stable PCLs for LV 
production, the recently construct-
ed constitutive WinPac cell line is a 
promising development. Compared 
to other constitutive LV PCLs [15], 
WinPac cells can produce third 
generation, self-inactivating LV at 
superior unconcentrated titers of 
106 transducing units (TU)/mL. 
Unlike other PCLs requiring induc-
ing agents, WinPac cells are suited 
to clinical production; however, the 
requirement for antibiotic selection 
of viral components limits their use 
in an up-scaled setting. According-
ly, moving away from an antibiot-
ic selection approach will favor the 
development of a PCL that is capa-
ble of scalable production. To date, 
WinPac cells have only been used to 
produce LVs with non-cytotoxic vi-
ral envelopes, although it would be 
possible to use an inducible expres-
sion construct for envelopes such as 
VSV-G [16]. 
LV production using  
transient transfection 
LVs are most commonly produced 
using multi-plasmid transient trans-
fection of adherent HEK 293T cells 
that are cultured in serum-con-
taining media [11]. Calcium-phos-
phate (CaP) and cationic polymer 
polyethylenimine (PEI) are the 
most economically feasible trans-
fection reagents for use in large-
scale production [17,18]. How-
ever, CaP-meditated transfection 
requires the presence of serum or 
albumin to reduce its cytotoxicity, 
and it is extremely sensitive to pH 
variations [19]. To minimize CaP 
toxicity to cells, a post-transfection 
media change is typically required, 
which is unfeasible in a large-scale 
production setting both practically 
and financially. PEI does not require 
tight regulation of transfection con-
ditions and it is also less toxic than 
CaP, therefore post-transfection 
media change is not necessary. PEI 
has also proven to be effective for 
the transfection of both adherent 
and suspension cultures, and can 
be used in either the presence or ab-
sence of serum [20]. 
Lipid-based transfection reagents 
(e.g., Lipofectamine, Invitrogen) 
have proven to be just as effective 
as CaP and PEI for LV production; 
however, these commercially avail-
able reagents are expensive, render-
ing them impractical for use at large 
scales [21]. Alternative non-chemi-
cal based methods such as flow elec-
troporation have been successfully 
employed for LV production, and 
are attractive for clinical-grade pro-
duction as they are good manufac-
turing practice (GMP) compliant 
[22]. However, this method requires 
further simplification before im-
plementing at an industrial scale as 
currently it requires the cells to be 
concentrated prior to transfection, 
which is challenging at large scales 
[23]. Transient transfection is more 
flexible and efficient than stable LV 
production methods, does not re-
quire time-consuming development 
of PCLs, and allows for use of cy-
totoxic viral components. Despite 
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these advantages, transient LV pro-
duction is not ideal for up-scaled 
manufacturing due to the need for 
large volumes of costly GMP grade 
plasmid DNA and transfection 
agent [9], poor batch-to-batch re-
producibility, increased complexity 
of DSP to remove impurities in-
troduced during transfection, and 
the risk of contaminating the final 
product with immunogenic plas-
mid DNA [24]. For GMP LV pro-
duction a consistent quality is nec-
essary, therefore a stable approach is 
preferred in the future.
Adherent cell approaches 
for up-scaling LV production 
Up-scaling LV production using 
adherent cells is labor intensive, al-
though modest increases have been 
achieved using multiple surface culti-
vation systems such as roller bottles, 
multi-layer flasks and cell factories. 
However, because these technologies 
are low cell density culture systems, 
up-scaling can only be achieved by 
increasing the number of production 
units (scale-out) rather than with an 
increase in unit size (scale-up) [9,10]. 
In an attempt to overcome the lack 
of scalability associated with con-
ventional 2D adherent culture sys-
tems, technologies such as hollow 
fiber bioreactors (e.g., the Quantum 
bioreactor, Terumo BCT) [25] and 
fixed-bed bioreactors (e.g., iCELLis 
500 system, Pall) have been devel-
oped [26]. These bioreactors provide 
large surface areas for the cultivation 
of adherent cells and can tightly 
regulate production parameters en-
abling optimized cell growth and 
productivity. Microcarriers can also 
be used to cultivate adherent cells 
at high densities by providing a sup-
port matrix for cell attachment that 
enables them to grow in stirred-tank 
and wave bioreactors [10]. 
Suspension cell approaches 
for up-scaling LV production 
Suspension cells have significant 
benefits over adherent cultures for 
up-scaling LV production. Suspen-
sion cells are easy to up-scale as they 
can be cultivated to much higher 
densities in systems such as stirred-
tank and wave bioreactors [27,28]. 
These reactors are equipped with 
controller units allowing for tight 
regulation of culture conditions 
and subsequent increases in cell 
growth and productivity [29]. Sus-
pension cells can also be cultured in 
serum-free media, thus favoring the 
move towards a clinical grade prod-
uct, and simplifying DSP. Replac-
ing scale-out adherent approaches 
with scale-up suspension processes 
also reduces the variability between 
virus batches, an important regula-
tory requirement [30]. 
There have been few reports of 
successful LV production using 
transient transfection of suspension 
HEK 293 cell lines in bioreactor sys-
tems [11,31]. Encouragingly though, 
studies indicate that suspension 
systems achieve similar titers to 
those routinely obtained using ad-
herent HEK 293T cells. Segura et 
al. (2007) investigated the use of 
PEI-mediated transient transfec-
tion of HEK 293 EBNA-1 suspen-
sion-adapted cells in a 3 L bioreactor 
where titers of 1 x 106 TU/mL were 
reported [11]. In a similar protocol 
developed by Ansorge et al. (2009), 
suspension HEK 293SF-3F6 cells 
were transiently transfected with 
PEI in a perfusion-based bioreac-
tor system with maximum titers of 
8 x 107 TU/mL achieved [31]. Flow 
electroporation has also been used 
to transfect suspension HEK 293FT 
cells in a 2 L working volume using 
a wave bioreactor system, with titers 
of 1 x 108 TU/mL produced [22]. 
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More recently, there have been 
reports of a suspension-adapted 
stable PCL used to generate LVs 
in bioreactor systems. Manceur et 
al. (2017) developed an inducible, 
stable HEK 293SF suspension cell 
line that was used to produce LVs 
at a 1–3 L scale using perfusion 
and batch mode approaches. Both 
systems achieved considerable ti-
ters, although the perfusion system 
proved to have increased yields of 
2 x 107 TU/mL compared to batch 
mode with 6 x 106 TU/mL [32]. 
These studies demonstrate that high 
titers can be achieved using sus-
pension cells in a bioreactor setup; 
however, use of a perfusion-based 
approach can be technically com-
plex as often multiple harvest steps 
are required, and it is also costly due 
to the need for large volumes of cul-
ture medium. Although promising, 
suspension based methods have not 
yet been adopted for routine LV 
production, suggesting that further 
optimization is needed. 
DOWNSTREAM 
PROCESSING 
DSP is critical for removing impu-
rities and contaminants that may 
otherwise compromise product 
safety and potency [8]. Establishing 
efficient DSP protocols for LVs has 
proven challenging. There is a lack 
of simple methods capable of rapid-
ly processing large volumes of vec-
tor supernatant, and the inherent 
instability of LVs attributed in part 
to the fragile nature of their lipid 
envelope, leaves particles vulner-
able to damage during processing 
[33]. As a result, purification and 
concentration techniques are often 
integrated together to create a step-
wise DSP approach. In an up-scaled 
DSP scenario, techniques should be 
cost-effective, have a high capacity 
and throughput, efficiently remove 
contaminants, and preserve vec-
tor function with minimal particle 
losses [34]. A number of LV puri-
fication and concentration meth-
ods have been reported including 
chromatography methods such as 
anion-exchange [35], size-exclusion 
[36] and affinity adsorption [37], 
as well as low and high-speed cen-
trifugation [38,39], and ultrafiltra-
tion techniques such as tangential 
flow filtration (TFF) [30] and spin 
filtration [40]. In general, develop-
ers should minimize the number of 
DSP steps used so that high levels of 
viral titer and function are retained 
[41]. The following section briefly 
overviews the currently available LV 
DSP methods. Titers and recoveries 
are provided only as an indication as 
direct comparisons are difficult due 
to differences in the LV vector sys-
tems, transgenes and titering proce-
dures used. 
Clarification
Clarification methods such as mi-
crofiltration and low speed centrif-
ugation are typically employed at 
the initial stages of DSP to remove 
impurities such as cells and other 
debris [41]. At small volumes, low 
speed centrifugation prior to micro-
filtration can improve clarity of the 
supernatant and reduce membrane 
fouling. However, for large-scale 
purification a single clarification 
step is preferred for streamlined 
processing. For example, a series of 
membranes with decreasing pore 
size (1 µm > 0.8 µm > 0.45 µm) 
have been used in a direct-flow set-
up to remove large impurities [42]. 
TFF can also be applied at both 
the initial bulk clarification and the 
downstream concentration stages. 
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TFF involves pumping superna-
tant tangentially along the surface 
of a membrane rather than direct-
ly into the filter, therefore reducing 
membrane fouling and allowing 
large volumes of supernatant to be 
processed. TFF is a relatively gentle 
clarification method and has proven 
to be effective for LV purification 
with reports of recoveries as high as 
90–100% following TFF, and yields 
ranging from 108 to 1010 TU/mL 
[30,43].  While TFF is an attractive 
option, the high recoveries reported 
here may be difficult to reproduce at 
large-scales. Shear stress is also con-
siderable at high flow rates, there-
fore in an up-scaled setting flow 
rates will need to be restricted, thus 
increasing processing time [44].
Purification 
Chromatography is a commonly 
used purification technology ideal 
for processing large volumes due to 
its scalability, rapid processing time 
and amenability to automation. One 
method, anion-exchange chroma-
tography (AEX), involves passing 
viral supernatant through a column 
where negatively charged virus par-
ticles bind to the positively charged 
chromatographic matrix. Bound 
particles are then eluted from the 
column using a high concentration 
salt buffer. AEX chromatography is 
an attractive option, as columns are 
available in a variety of sizes, can 
be connected in a series to increase 
binding area, and are reusable, thus 
reducing purification costs. AEX 
produces vector of high purity, how-
ever exposure to high ionic strength 
solutions during the elution step can 
considerably reduce the infectivity of 
the LV particles [45]. In one study, 
recoveries following AEX were on 
average, 50%, with concentrated ti-
ters of 2 x 108 TU/mL achieved [46]. 
A second method is affinity ad-
sorption chromatography, regularly 
used in the pharmaceutical indus-
try to isolate biomolecules [11]. 
Heparin affinity chromatography 
is effective for purification of LVs, 
and involves loading supernatant 
onto a column where the virus par-
ticles bind to heparin ligands that 
are immobilized on a chromato-
graphic gel. Elution of the vector 
particles is achieved using mild 
conditions with only a low mo-
larity salt solution required, thus 
preserving vector infectivity [37]. 
Heparin affinity has been shown to 
be suitable for processing large vol-
umes, although it has disadvantag-
es including the need for additional 
purification of the eluate to remove 
impurities that bind to the column 
and are co-released with the vector 
during desorption [47]. Recoveries 
following use of heparin affinity 
chromatography in one study were 
reported at 53%, with a titer of 1010 
TU attained [11]. Further in-depth 
understanding of LV envelope 
composition will benefit the devel-
opment of other affinity adsorption 
methods in the future [48].  
A third option is size exclusion 
chromatography (SEC), also known 
as gel filtration. SEC is a non-ad-
sorptive technique that separates 
virus particles from contaminants 
on the basis of size and mass [34]. 
It is a powerful technique, yet uses 
gentler conditions compared to 
other chromatography methods as 
no virus binding or elution occurs 
[41]. Although high recoveries of up 
to 70% and titers of 8 x 107 TU/
mL have been achieved following 
SEC [36], it may not be suitable 
for large-scale DSP as it has a low 
throughput, requires low linear flow 
rates that increase processing times, 
and further concentration steps 
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are usually needed as there is a di-
lution effect. Given this, SEC may 
be more suitable for use in the final 
stages of purification to act as a pol-
ishing step [23,34].
Concentration 
Concentration is used to obtain 
smaller volumes of the vector prepa-
ration either for final formulation, 
or to reduce the feed volume for 
subsequent processing steps. De-
pending on the DSP protocol used, 
concentration factors ranging any-
where between 10- and 2000-fold 
can be achieved [23]. Virus pelleting 
by high-speed ultracentrifugation 
and low-speed centrifugation (usu-
ally several hours) are both com-
monly used for the concentration of 
LVs [41]. Centrifugation is capable 
of achieving concentration factors 
greater than 100-fold by resuspen-
sion of the viral pellets in small vol-
umes of the final formulation [48]. 
Although a time-efficient approach, 
ultracentrifugation has disadvantag-
es including the co-concentration 
of impurities that may be inhibitory 
to vector performance [36], losses of 
functional vector particles due to 
shear stress, unsuitability for certain 
viral pseudotypes [49], and limited 
scalability due to the small volume 
capacity of ultra-high-speed rotors 
[38]. Concentrating LVs using ultra-
centrifugation can yield high titers 
of 109 to 1010 TU/mL, and recov-
eries between 60 and 90% [40,50]. 
Low-speed centrifugation for long 
durations is a more gentle approach 
compared to ultracentrifugation, 
which is ideal for vectors with sen-
sitive pseudotypes, and often results 
in higher infectious particle recov-
eries [39]. It is also more amenable 
to up-scaling compared to ultra-
centrifugation, as low-speed rotors 
have a larger volume capacity [51]. 
Previous reports using low speed 
centrifugation have demonstrated 
recoveries above 80%, with titers of 
2 x 108 TU/mL [39].
As already noted, ultrafiltration is 
a suitable alternative for concentrat-
ing LVs. Ultrafiltration allows for 
mild processing conditions, is typi-
cally scalable, and can be carried out 
using a variety of devices, although 
the achievable concentration fac-
tors are often lower [30,45]. For in-
stance, when processing LVs using 
TFF, viral particles are retained by 
the membrane while smaller impu-
rities are removed, resulting in a net 
concentration of vector [30]. Low 
speed spin filtration using centrifu-
gal ultrafiltration devices (e.g., Cen-
tricon columns) is also an effective 
method for concentrating LVs and 
has the potential to be up-scaled 
by using larger centrifuge rotors. 
Centrifugal filtration has previous-
ly demonstrated negligible particle 
losses and high titers of 109 to 1010 
TU/mL [40,50]. 
TRANSLATIONAL INSIGHT 
One of the main hurdles for suc-
cessful translation of candidate gene 
therapies to the clinic is producing 
adequate volumes of LV vector. The 
scale of LV production required for 
clinical and commercial use will 
depend on several factors includ-
ing the specific gene or cell thera-
py application, whether the route 
of delivery is ex vivo or in vivo, the 
target organ/tissue, disease patho-
genesis and whether repeat dosing 
will be required [52]. It is difficult to 
speculate the exact LV quantity re-
quirements given this diverse range 
of applications, although current 
successful ex vivo gene therapy trials 
have used 1 to 40 x 109 infectious 
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units of vector per patient [3,53]. 
It is likely that estimates for in vivo 
gene therapy applications will be 
much higher. Nonetheless, a work-
flow capable of economical, large-
scale LV production and processing 
is required.
Along with high-titers, 
high-quality LV samples are nec-
essary to achieve the desired thera-
peutic outcome, while minimizing 
adverse side effects. All LV vector 
preparations intended for clinical 
use must undergo rigorous testing 
to certify their potency and safety. 
Potency (titer) is typically estimat-
ed by determining the number of 
infectious particles (e.g., real-time 
quantitative PCR assay), as well as 
the total number of particles in-
cluding those that are non-func-
tional (e.g., p24 ELISA) [54]. Rou-
tine quality control analyses are 
also necessary to detect potentially 
toxic or immunogenic impurities. 
Contaminants such as proteins and 
DNA secreted from producer cell 
lines, plasmid DNA and reagents 
carried over from transient trans-
fection, and potential transduction 
inhibitors such as free-floating en-
velope proteins and non-infectious 
particles should be quantified in 
each preparation [34]. Sensitive as-
says must also be used to screen LV 
vector batches and producer cells 
for the absence of replication-com-
petent lentiviruses (RCLs), which 
could arise as a result of homolo-
gous recombination events [55]. As 
LV gene therapy products are rela-
tively new for regulatory authori-
ties, it is likely that regulations and 
guidance will increase as products 
are taken to clinical trial and more 
information is released [56].
Over the past decade there 
have been considerable advances 
in state-of-the-art LV production. 
Transient transfection methods 
are continuing to be pursued for 
up-scaling, which has led to es-
tablishment of cultivation systems 
that considerably increase cell 
densities. Technologies including 
hollow fiber bioreactors, fixed-
bed bioreactors and microcarriers 
have been developed to increase 
the productivity of adherent sys-
tems. More recently, HEK 293T 
cell lines have been adapted to 
suspension culture thereby allow-
ing LVs to be produced in scalable 
bioreactor systems such as stirred-
tanks and wave bags. For future 
commercial-scale manufacturing a 
stable, suspension-based approach 
is the ideal solution, as it is highly 
scalable, lower cost, and more ap-
pealing from a regulatory perspec-
tive. Despite ongoing challenges 
surrounding the development of 
high-titer PCLs, recent progress 
including the development of the 
clinical-grade WinPac PCL, and 
successful production of LVs us-
ing a stable, suspension-adapted 
HEK 293SF cell line, suggest that 
a suitable PCL may not be far from 
realization. Along with advances in 
USP, there have also been signifi-
cant developments in DSP, with a 
number of established techniques 
available for the purification and 
concentration of LVs. Work is now 
ongoing to validate and optimize 
these methods at the large scales 
needed for commercial produc-
tion. For up-scaled manufactur-
ing, a complete DSP scheme from 
crude LV supernatant to the final 
clinical-grade product is likely to 
consist of a multi-step workflow 
that efficiently clarifies, isolates, 
and concentrates LVs. 
Moving forward, there are 
key milestones that must be 
achieved for successful commercial 
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manufacturing of LVs. Firstly, a 
scalable, suspension-based biopro-
cess that can consistently produce 
high-titer LV in large batches much 
be established. Although transient 
transfection may be sufficient in 
the interim, a stable expression ap-
proach using PCLs is preferred. In 
accordance with this, a DSP work-
flow capable of efficiently handling 
large volumes of vector supernatant, 
while maintaining high recoveries, 
purity and function, will be essen-
tial. Finally, reducing the COGs as-
sociated with vector manufacturing 
will be necessary for LV-based gene 
therapies to become mainstream. 
Adopting a stable LV production 
approach would be a major step in 
achieving economic feasibility, as 
this eliminates the need for large 
amounts of costly GMP-grade plas-
mid DNA. As the gene therapy field 
continues to progress, accelerating 
the development of scalable LV 
production methods will be criti-
cal in bringing these treatments to 
fruition. 
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